KDR and breast cancer: Although this scenario remains speculative and does not rule out the contribution of other mechanisms to the development of acquired refractoriness, including VEGFR2 downregulation in B-TECs [77], it could explain the limited increase in OS and PFS observed in BC patients treated with anti-angiogenic inhibitors.